Martin Sanda, MD

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (175 ratings)

Role

Urology
Specialty

Prostate Cancer Bladder Cancer
Research Program

Cancer Prevention and Control
Practicing Since

1995

Call 404-778-4898

Background

In February of 2013, Martin G. Sanda, MD, an internationally recognized prostate cancer surgeon and scientist, was appointed Chair of the Department of Urology at Emory University School of Medicine and service chief for Emory Healthcare. In that capacity, he will also serve as Director of the Prostate Cancer Center, which will be established within Emory’s Winship Cancer Institute.

Sanda joins Emory from Harvard Medical School, where he was Professor of Surgery in urology, and from Beth Israel Deaconess Medical Center, where he served as Director of the Prostate Cancer Center. He was also the co-leader of the Prostate Cancer Program at the Dana Farber Cancer Center.
Sanda is principal investigator of three multi-center consortium studies funded by the National Cancer Institute and the Prostate Cancer Foundation that seek to develop urine tests for detecting prostate cancer; to develop benchmarks for improving quality of life among cancer survivors; and to develop innovative prostate cancer vaccines. These studies have enrolled over 4,400 patients with findings published in leading medical journals including the Journal of the American Medical Association and the New England Journal of Medicine.

Sanda’s clinical practice, which includes robotic prostatectomy and robotic cystectomy, is focused on developing new surgical and non-surgical approaches to cancer care and to improving the quality of life among cancer survivors.After receiving his BA in molecular biophysics and biochemistry from Yale University cum laude in 1983, Sanda went on to receive his MD degree at Columbia University in 1987. He then trained as a general surgery resident at the Medical College of Virginia and as a surgical oncology fellow at the National Cancer Institute. He completed his urology residency at Johns Hopkins Hospital.

Sanda has served as Chair of the Prostate and Genito-Urinary Collaborative Group of the National Cancer Institute’s Early Detection Research Network (2007-2010), has spearheaded two nationwide, NCI Cooperative Group prostate cancer clinical trials, has served on numerous federal funding review panels, and has served on the Research Council of the American Urological Association since 2011. Sanda has more than 150 peer-reviewed publications, and his work has been cited more than 5,000 times in biomedical literature.

Titles & Roles

Professor, Department of Urology

Emory University School of Medicine

Education & Training

Education

Residency, Urology, 1995
Johns Hopkins Hospital
Fellowship, Surgical Oncology, 1991
National Cancer Institute
Residency, General Surgery, 1989
Medical College of Virginia
Medical Education, MD, 1987
Columbia University College of Physician and Surgeons

Board Certifications

Urology
American Board of Urology, 1997

Research

View Current Clinical Trials


EDRN Prostate MRI Biomarker Study Phase Early Phase I Conditions PSA, Prostate Cancer Location Winship Cancer Institute

Grants

View Grants

Grant Number	Title
2U01CA113913-16A1	Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas Southwestern
5U01CA113913-17	Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas Southwestern

Publications

Title/Journal	Authors	Publication Date
Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States. Cancer	NT Sebastian, D Patil, PR Patel, AB Jani, BW Hershatter, VR Dhere, KD Godette, CA Lorentz, AD Weiss, SS Joshi, MG Sanda, SA Patel	03/15/2025
A simplified MyProstateScore2.0 for high-grade prostate cancer. Cancer biomarkers : section A of Disease markers	TM Tang, Y Zhang, AM Kenney, C Xie, L Xiao, J Siddiqui, S Srivastava, MG Sanda, JT Wei, Z Feng, JJ Tosoian, Y Zheng, AM Chinnaiyan, B Yu	01/01/2025
Epigenetic remodeling and 3D chromatin reorganization governed by NKX2-1 drive neuroendocrine prostate cancer. bioRxiv : the preprint server for biology	X Lu, V Keo, I Cheng, W Xie, G Gritsina, J Wang, Q Jin, P Jin, F Yue, MG Sanda, V Corces, N Altemose, JC Zhao, J Yu	12/07/2024
Differentiation fate of a stem-like CD4 T cell controls immunity to cancer. Nature	MA Cardenas, N Prokhnevska, E Sobierajska, P Gregorova, CB Medina, RM Valanparambil, R Greenwald, L DelBalzo, MA Bilen, SS Joshi, VM Narayan, VA Master, MG Sanda, HT Kissick	12/01/2024
Upgrading of Grade Group 1 Prostate Cancer at Prostatectomy: Germline Risk Factors in a Prospective Cohort. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology	MA Liss, N Zeltser, Y Zheng, C Lopez, M Liu, Y Patel, TN Yamaguchi, SE Eng, M Tian, OJ Semmes, DW Lin, JD Brooks, JT Wei, EA Klein, AK Tewari, JM Mosquera, F Khani, BD Robinson, M Aasad, DA Troyer, J Kagan, MG Sanda, IM Thompson, PC Boutros, RJ Leach	11/01/2024
The diagnostic challenges of differentiating metastatic extramammary Paget disease and prostatic adenocarcinoma: A case report and review of the literature. Urology case reports	G Palmateer, EH Nicaise, J Gandhi, T Goodstein, M Sheng, K Ogan, O Kucuk, M Yushak, MG Sanda, KA Delman, V Master	11/01/2024
Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life. JAMA network open	SA Patel, D Patil, J Smith, CS Saigal, MS Litwin, JC Hu, MR Cooperberg, PR Carroll, EA Klein, AS Kibel, GL Andriole, M Han, JM Michalski, DP Wood, LA Hembroff, DE Spratt, JT Wei, HM Sandler, DA Hamstra, L Pisters, D Kuban, MM Regan, A Wagner, CM Crociani, I Kaplan, MG Sanda, P Chang	10/01/2024
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer. JAMA oncology	JJ Tosoian, Y Zhang, L Xiao, C Xie, NL Samora, YS Niknafs, Z Chopra, J Siddiqui, H Zheng, G Herron, N Vaishampayan, HS Robinson, K Arivoli, BJ Trock, AE Ross, TM Morgan, GS Palapattu, SS Salami, LP Kunju, SA Tomlins, LJ Sokoll, DW Chan, S Srivastava, Z Feng, MG Sanda, Y Zheng, JT Wei, AM Chinnaiyan	06/01/2024
Integrated Genomic Analysis of Primary Prostate Tumor Foci and Corresponding Lymph Node Metastases Identifies Mutations and Pathways Associated with Metastasis. Cancers	CS Moreno, CL Winham, M Alemozaffar, ER Klein, IO Lawal, OA Abiodun-Ojo, D Patil, BG Barwick, Y Huang, DM Schuster, MG Sanda, AO Osunkoya	11/30/2023
Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	JM Michalski, KA Winter, BR Prestidge, MG Sanda, M Amin, WS Bice, HA Gay, GS Ibbott, JM Crook, CN Catton, A Raben, W Bosch, DC Beyer, SJ Frank, MA Papagikos, SA Rosenthal, HJ Barthold, M Roach, J Moughan, HM Sandler	08/20/2023
Covariate-specific evaluation of continuous biomarker. Statistics in medicine	Z Li, Y Huang, D Patil, M Rubin, MG Sanda	03/30/2023
Covariate adjustment in continuous biomarker assessment. Biometrics	Z Li, Y Huang, D Patil, MG Sanda	03/01/2023
CD8⁺ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor. Immunity	N Prokhnevska, MA Cardenas, RM Valanparambil, E Sobierajska, BG Barwick, C Jansen, A Reyes Moon, P Gregorova, L delBalzo, R Greenwald, MA Bilen, M Alemozaffar, S Joshi, C Cimmino, C Larsen, V Master, M Sanda, H Kissick	01/10/2023
Interval estimation for operating characteristic of continuous biomarkers with controlled sensitivity or specificity. Statistica Sinica	Y Huang, I Parakati, DH Patil, MG Sanda	01/01/2023
Invariant NKT cell-augmented GM-CSF-secreting tumor vaccine is effective in advanced prostate cancer model. Cancer immunology, immunotherapy : CII	B Varghese, L Lynch, LE Vriend, D Draganov, JM Clark, HT Kissick, S Varghese, MG Sanda, G Dranoff, MS Arredouani, SP Balk, MA Exley	12/01/2022
Cost-effectiveness analysis of primary treatments for localised prostate cancer: A population-based Markov analysis using real-world evidence. European journal of cancer care	X Weng, L Zhong, P Xiang, Y Li, A Paciorek, L Dong, J Broering, PR Carroll, M Sanda, L Wilson	11/01/2022
Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. The Journal of urology	CP Filson, K Zhu, Y Huang, Y Zheng, LF Newcomb, S Williams, JD Brooks, PR Carroll, A Dash, WJ Ellis, ME Gleave, MA Liss, F Martin, JK McKenney, TM Morgan, AA Wagner, LJ Sokoll, MG Sanda, DW Chan, DW Lin	11/01/2022
LINEAR BIOMARKER COMBINATION FOR CONSTRAINED CLASSIFICATION. Annals of statistics	Y Huang, MG Sanda	10/01/2022
Patient reported outcomes for quality of life (QOL) by Expanded Prostate Cancer Index (EPIC) on average 15 years post treatment. Clinical and translational radiation oncology	ZA Seymour, S Daignault-Newton, PW McLaughlin, H Sandler, W Jackson, SB Johnson, D Miller, J Wei, M Sanda, DA Hamstra	09/01/2022
High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells. Nature communications	M Boya, T Ozkaya-Ahmadov, BE Swain, CH Chu, N Asmare, O Civelekoglu, R Liu, D Lee, S Tobia, S Biliya, LD McDonald, B Nazha, O Kucuk, MG Sanda, BB Benigno, CS Moreno, MA Bilen, JF McDonald, AF Sarioglu	06/13/2022
Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer. European urology open science	BW Fischer-Valuck, BC Baumann, SA Brown, CP Filson, A Weiss, R Mueller, Y Liu, RJ Brenneman, M Sanda, JM Michalski, HA Gay, Y James Rao, JG Pattaras, AB Jani, B Hershatter, SA Patel	03/01/2022
Association of race with receipt of definitive therapy for high risk prostate cancer in older men. Journal of geriatric oncology	SA Patel, Y Liu, BA Mahal, AB Jani, MG Sanda, TJ Royce, BW Fischer-Valuck	03/01/2022
Cancer-specific outcomes for prostate cancer patients who had prebiopsy prostate MRI. Urologic oncology	J Li, D Patil, MG Sanda, CP Filson	02/01/2022
Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment. HGG advances	Y Jiang, TJ Meyers, AA Emeka, LF Cooley, PR Cooper, N Lancki, I Helenowski, L Kachuri, DW Lin, JL Stanford, LF Newcomb, S Kolb, A Finelli, NE Fleshner, M Komisarenko, JA Eastham, B Ehdaie, N Benfante, CJ Logothetis, JR Gregg, CA Perez, S Garza, J Kim, LS Marks, M Delfin, D Barsa, D Vesprini, LH Klotz, A Loblaw, A Mamedov, SL Goldenberg, CS Higano, M Spillane, E Wu, HB Carter, CP Pavlovich, M Mamawala, T Landis, PR Carroll, JM Chan, MR Cooperberg, JE Cowan, TM Morgan, J Siddiqui, R Martin, EA Klein, K Brittain, P Gotwald, DA Barocas, JR Dallmer, JB Gordetsky, P Steele, SD Kundu, J Stockdale, MJ Roobol, LDF Venderbos, MG Sanda, R Arnold, D Patil, CP Evans, MA Dall'Era, A Vij, AJ Costello, K Chow, NM Corcoran, S Rais-Bahrami, C Phares, DS Scherr, T Flynn, RJ Karnes, M Koch, CR Dhondt, JB Nelson, D McBride, MS Cookson, KL Stratton, S Farriester, E Hemken, WM Stadler, T Pera, D Banionyte, FJ Bianco, IH Lopez, S Loeb, SS Taneja, N Byrne, CL Amling, A Martinez, L Boileau, FD Gaylis, J Petkewicz, N Kirwen, BT Helfand, J Xu, DM Scholtens, WJ Catalona, JS Witte	01/13/2022
Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium. The Journal of urology	P Chang, AA Wagner, MM Regan, JA Smith, CS Saigal, MS Litwin, JC Hu, MR Cooperberg, PR Carroll, EA Klein, AS Kibel, GL Andriole, M Han, AW Partin, DP Wood, CM Crociani, TK Greenfield, D Patil, LA Hembroff, K Davis, L Stork, DE Spratt, JT Wei, MG Sanda	01/01/2022
Disparities in magnetic resonance imaging of the prostate for traditionally underserved patients with prostate cancer. Cancer	TP Quinn, MG Sanda, DH Howard, D Patil, CP Filson	08/15/2021
Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial. Urologic oncology	DL Berry, F Hong, TM Blonquist, B Halpenny, N Xiong, CP Filson, VA Master, MG Sanda, P Chang, GW Chien, RA Jones, TL Krupski, S Wolpin, L Wilson, JH Hayes, QD Trinh, M Sokoloff	08/01/2021
A panel of selected serum protein biomarkers for the detection of aggressive prostate cancer. Theranostics	J Song, S Ma, LJ Sokoll, RV Eguez, N Höti, H Zhang, P Mohr, R Dua, D Patil, KD May, S Williams, R Arnold, MG Sanda, DW Chan, Z Zhang	01/01/2021
Prostate Cancer Biomarker Development: National Cancer Institute's Early Detection Research Network Prostate Cancer Collaborative Group Review. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology	MA Liss, RJ Leach, MG Sanda, OJ Semmes	12/01/2020
[¹⁸F]Fluciclovine Positron Emission Tomography/Computerized Tomography for Preoperative Staging in Patients with Intermediate to High Risk Primary Prostate Cancer. The Journal of urology	M Alemozaffar, AA Akintayo, OA Abiodun-Ojo, D Patil, F Saeed, Y Huang, AO Osunkoya, MM Goodman, M Sanda, DM Schuster	10/01/2020
In-Bore MRI-guided Prostate Biopsies in Patients with Prior Positive Transrectal US-guided Biopsy Results: Pathologic Outcomes and Predictors of Missed Cancers. Radiology. Imaging cancer	KK Elfatairy, CP Filson, MG Sanda, AO Osunkoya, SG Nour	09/25/2020
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	JA Eastham, G Heller, S Halabi, JP Monk, H Beltran, M Gleave, CP Evans, SK Clinton, RZ Szmulewitz, J Coleman, DW Hillman, CR Watt, S George, MG Sanda, OM Hahn, ME Taplin, JK Parsons, JL Mohler, EJ Small, MJ Morris	09/10/2020
A prospective study of patient reported urinary incontinence among American, Norwegian and Spanish men 1 year after prostatectomy. Asian journal of urology	AH Storås, MG Sanda, O Garin, P Chang, D Patil, C Crociani, JF Suarez, M Cvancarova, JH Loge, SD Fosså	04/01/2020
An intra-tumoral niche maintains and differentiates stem-like CD8 T cells. Nature	CS Jansen, N Prokhnevska, VA Master, MG Sanda, JW Carlisle, MA Bilen, M Cardenas, S Wilkinson, R Lake, AG Sowalsky, RM Valanparambil, WH Hudson, D McGuire, K Melnick, AI Khan, K Kim, YM Chang, A Kim, CP Filson, M Alemozaffar, AO Osunkoya, P Mullane, C Ellis, R Akondy, SJ Im, AO Kamphorst, A Reyes, Y Liu, H Kissick	12/01/2019
In-Bore MRI-guided Prostate Biopsies: Retrospective Observational Study of Complementary Nontargeted Sampling of Normal-appearing Areas at Multiparametric MRI. Radiology. Imaging cancer	KK Elfatairy, CP Filson, MG Sanda, AO Osunkoya, SG Nour	11/01/2019
A four-group urine risk classifier for predicting outcomes in patients with prostate cancer. BJU international	SP Connell, M Yazbek-Hanna, F McCarthy, R Hurst, M Webb, H Curley, H Walker, R Mills, RY Ball, MG Sanda, KL Pellegrini, D Patil, AS Perry, J Schalken, H Pandha, H Whitaker, N Dennis, C Stuttle, IG Mills, I Guldvik, C Parker, DS Brewer, CS Cooper, J Clark	10/01/2019
Rise in Node-Positive Prostate Cancer Incidence in Context of Evolving Use and Extent of Pelvic Lymphadenectomy. Clinical genitourinary cancer	MA Taylor, M Alemozaffar, VA Master, MG Sanda, CP Filson	06/01/2019
Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy. The Prostate	AC McDonald, M Vira, V Walter, J Shen, JD Raman, MG Sanda, D Patil, E Taioli	06/01/2019
Expanded Prostate Cancer Index Composite-26 (EPIC-26) Online: Validation of an Internet-Based Instrument for Assessment of Health-Related Quality of Life After Treatment for Localized Prostate Cancer. Urology	DJ Einstein, D Patil, J Chipman, MM Regan, K Davis, CM Crociani, AA Wagner, MG Sanda, P Chang	05/01/2019
Impact of prebiopsy magnetic resonance imaging of the prostate on cancer detection and treatment patterns. Urologic oncology	W Liu, D Patil, DH Howard, RH Moore, H Wang, MG Sanda, CP Filson	03/01/2019
Evaluating Clinical Implementation Approaches for Prostate Cancer Decision Support. Urology practice	DL Berry, F Hong, B Halpenny, MG Sanda, VA Master, CP Filson, P Chang, GW Chien, M Underhill, E Fox, J McReynolds, S Wolpin	03/01/2019
Genitourinary Prosthetic Use among Prostate Cancer Survivors Treated with Radical Prostatectomy. Urology practice	LA Aliperti, D Patil, CP Filson, LM Hartsell, KJ Carney, MG Sanda, A Mehta	03/01/2019
Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Clinical genitourinary cancer	C Vicier, L Werner, J Chipman, LC Harshman, DH Patil, RN Fichorova, JR Rider, MG Sanda, LA Mucci, CJ Sweeney	02/01/2019
Assigning value to preparation for prostate cancer decision making: a willingness to pay analysis. BMC medical informatics and decision making	LS Wilson, TM Blonquist, F Hong, B Halpenny, S Wolpin, P Chang, CP Filson, VA Master, MG Sanda, GW Chien, RA Jones, TL Krupski, DL Berry	01/09/2019
High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores. Brachytherapy	TM Morgan, PJ Rossi, PK Cutrell, C Zhang, RH Press, S Rahnema, M Sanda, J Pattaras, C Cimmino, B Hershatter, AB Jani, PR Patel	01/01/2019
Patient-reported health-related quality of life outcomes after HDR brachytherapy between small (<60 cc) and large (≥60 cc) prostate glands. Brachytherapy	RH Press, TM Morgan, PK Cutrell, C Zhang, Z Chen, S Rahnema, M Sanda, J Pattaras, P Patel, AB Jani, PJ Rossi	01/01/2019
Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator. European urology focus	DP Ankerst, M Goros, SA Tomlins, D Patil, Z Feng, JT Wei, MG Sanda, J Gelfond, IM Thompson, RJ Leach, MA Liss	01/01/2019
epiCaPture: A Urine DNA Methylation Test for Early Detection of Aggressive Prostate Cancer. JCO precision oncology	E O'Reilly, AV Tuzova, AL Walsh, NM Russell, O O'Brien, S Kelly, ON Dhomhnallain, L DeBarra, CM Dale, R Brugman, G Clarke, O Schmidt, S O'Meachair, D Patil, KL Pellegrini, N Fleshner, J Garcia, F Zhao, S Finn, R Mills, MY Hanna, R Hurst, E McEvoy, WM Gallagher, RP Manecksha, CS Cooper, DS Brewer, B Bapat, MG Sanda, J Clark, AS Perry	01/01/2019
Brachytherapy for localized prostate cancer in the modern era: a comparison of patient-reported quality of life outcomes among different techniques. Journal of contemporary brachytherapy	TM Morgan, RH Press, PK Cutrell, C Zhang, Z Chen, S Rahnema, M Sanda, J Pattaras, PR Patel, AB Jani, PJ Rossi	12/01/2018
Adoption of Prebiopsy Magnetic Resonance Imaging for Men Undergoing Prostate Biopsy in the United States. Urology	W Liu, D Patil, DH Howard, RH Moore, H Wang, MG Sanda, CP Filson	07/01/2018
Hypofractionated external beam radiation therapy in combination with HDR boost for localized prostate cancer: patient reported quality of life outcomes. Journal of contemporary brachytherapy	TM Morgan, RH Press, PK Cutrell, C Zhang, Z Chen, S Rahnema, J Jhaveri, M Sanda, J Pattaras, P Patel, AB Jani, PJ Rossi	06/01/2018
Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis. Cancer treatment reviews	M Ávila, L Patel, S López, L Cortés-Sanabria, O Garin, À Pont, F Ferrer, A Boladeras, V Zamora, S Fosså, AH Storås, M Sanda, V Serra-Sutton, M Ferrer	05/01/2018
Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer. The Prostate	AC McDonald, M Vira, J Shen, M Sanda, JD Raman, J Liao, D Patil, E Taioli	05/01/2018
In-bore MRI-guided biopsy: can it optimize the need for periodic biopsies in prostate cancer patients undergoing active surveillance? A pilot test-retest reliability study. The British journal of radiology	KK Elfatairy, CP Filson, MG Sanda, AO Osunkoya, RL Geller, SG Nour	04/01/2018
Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. Practical radiation oncology	SA Mihalcik, JJ Chipman, MG Sanda, MM Regan, ID Kaplan, AA Wagner, CM Crociani, P Chang	01/01/2018
Decision Support with the Personal Patient Profile-Prostate: A Multicenter Randomized Trial. The Journal of urology	DL Berry, F Hong, TM Blonquist, B Halpenny, CP Filson, VA Master, MG Sanda, P Chang, GW Chien, RA Jones, TL Krupski, S Wolpin, L Wilson, JH Hayes, QD Trinh, M Sokoloff, P Somayaji	01/01/2018
Patients with Intermediate Risk Prostate Cancer May be Good Candidates for Active Surveillance: Pro. The Journal of urology	MG Sanda	11/01/2017
Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. JAMA oncology	MG Sanda, Z Feng, DH Howard, SA Tomlins, LJ Sokoll, DW Chan, MM Regan, J Groskopf, J Chipman, DH Patil, SS Salami, DS Scherr, J Kagan, S Srivastava, IM Thompson, J Siddiqui, J Fan, AY Joon, LE Bantis, MA Rubin, AM Chinnayian, JT Wei, M Bidair, A Kibel, DW Lin, Y Lotan, A Partin, S Taneja	08/01/2017
Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4. Clinical cancer research : an official journal of the American Association for Cancer Research	AG Sowalsky, HT Kissick, SJ Gerrin, RJ Schaefer, Z Xia, JW Russo, MS Arredouani, GJ Bubley, MG Sanda, W Li, H Ye, SP Balk	07/15/2017
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. BJU international	S Loeb, SS Shin, DL Broyles, JT Wei, M Sanda, G Klee, AW Partin, L Sokoll, DW Chan, CH Bangma, RHN van Schaik, KM Slawin, LS Marks, WJ Catalona	07/01/2017
Racial Variation in the Utility of Urinary Biomarkers PCA3 and T2ERG in a Large Multicenter Study. The Journal of urology	PG O'Malley, DP Nguyen, B Al Hussein Al Awamlh, G Wu, IM Thompson, M Sanda, M Rubin, JT Wei, R Lee, P Christos, C Barbieri, DS Scherr	07/01/2017
Evaluation of a 24-gene signature for prognosis of metastatic events and prostate cancer-specific mortality. BJU international	KL Pellegrini, MG Sanda, D Patil, Q Long, M Santiago-Jiménez, M Takhar, N Erho, K Yousefi, E Davicioni, EA Klein, RB Jenkins, RJ Karnes, CS Moreno	06/01/2017
External Beam Radiation Therapy or Brachytherapy With or Without Short-course Neoadjuvant Androgen Deprivation Therapy: Results of a Multicenter, Prospective Study of Quality of Life. International journal of radiation oncology, biology, physics	HA Gay, MG Sanda, J Liu, N Wu, DA Hamstra, JT Wei, RL Dunn, EA Klein, HM Sandler, CS Saigal, MS Litwin, DA Kuban, L Hembroff, MM Regan, P Chang, JM Michalski	06/01/2017
Detection of prostate cancer-specific transcripts in extracellular vesicles isolated from post-DRE urine. The Prostate	KL Pellegrini, D Patil, KJS Douglas, G Lee, K Wehrmeyer, M Torlak, J Clark, CS Cooper, CS Moreno, MG Sanda	06/01/2017
Neoadjuvant Enzalutamide Prior to Prostatectomy. Clinical cancer research : an official journal of the American Association for Cancer Research	B Montgomery, MS Tretiakova, AM Joshua, ME Gleave, N Fleshner, GJ Bubley, EA Mostaghel, KN Chi, DW Lin, M Sanda, W Novotny, K Wu, PW Kantoff, BT Marck, S Plymate, SP Balk, PS Nelson, AM Matsumoto, RT Lis, A Kibel, GP Haas, A Krivoshik, A Hannah, ME Taplin	05/01/2017
Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment. The Journal of urology	P Chang, MM Regan, M Ferrer, F Guedea, D Patil, JT Wei, LA Hembroff, JM Michalski, CS Saigal, MS Litwin, DA Hamstra, ID Kaplan, JP Ciezki, EA Klein, AS Kibel, HM Sandler, RL Dunn, CM Crociani, MG Sanda	02/01/2017
Clinical Use of Expanded Prostate Cancer Index Composite for Clinical Practice to Assess Patient Reported Prostate Cancer Quality of Life Following Robot-Assisted Radical Prostatectomy. The Journal of urology	AA Wagner, PJ Cheng, A Carneiro, O Dovirak, A Khosla, KN Taylor, CM Crociani, KC McAnally, A Percy, LE Dewey, MG Sanda, P Chang	01/01/2017
Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. International journal of radiation oncology, biology, physics	JY Lee, S Daignault-Newton, G Heath, S Scarlett, MG Sanda, P Chang, MM Regan, JM Michalski, HM Sandler, FY Feng, DA Kuban, AL Zietman, JP Ciezki, ID Kaplan, C Crociani, WP McLaughlin, CA Mantz, SE Finkelstein, S Suy, SP Collins, O Garin, M Ferrer, DA Hamstra, DE Spratt	11/15/2016
Erectile Dysfunction and Sexual Problems Two to Three Years After Prostatectomy Among American, Norwegian, and Spanish Patients. Clinical genitourinary cancer	AH Storås, MG Sanda, OG Boronat, P Chang, D Patil, C Crociani, JF Suarez, M Cvancarova, JH Loge, SD Fosså	06/01/2016
Gleason Misclassification Rate Is Independent of Number of Biopsy Cores in Systematic Biopsy. Urology	L Quintana, A Ward, SJ Gerrin, EM Genega, S Rosen, MG Sanda, AA Wagner, P Chang, WC DeWolf, H Ye	05/01/2016
RNA biomarkers to facilitate the identification of aggressive prostate cancer. Molecular aspects of medicine	KL Pellegrini, MG Sanda, CS Moreno	11/01/2015
Quality of life after primary treatment for localized prostate cancer: long-term considerations. European urology	M Alemozaffar, MG Sanda	10/01/2015
The transcription factor ERG increases expression of neurotransmitter receptors on prostate cancer cells. BMC cancer	HT Kissick, ST On, LK Dunn, MG Sanda, JM Asara, KL Pellegrini, JK Noel, MS Arredouani	08/27/2015
The role of active vaccination in cancer immunotherapy: lessons from clinical trials. Current opinion in immunology	HT Kissick, MG Sanda	08/01/2015
Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology	JR Evans, S Zhao, S Daignault, MG Sanda, J Michalski, HM Sandler, DA Kuban, J Ciezki, ID Kaplan, AL Zietman, L Hembroff, FY Feng, S Suy, TA Skolarus, PW McLaughlin, JT Wei, RL Dunn, SE Finkelstein, CA Mantz, SP Collins, DA Hamstra	08/01/2015
Usability evaluation and adaptation of the e-health Personal Patient Profile-Prostate decision aid for Spanish-speaking Latino men. BMC medical informatics and decision making	DL Berry, B Halpenny, JLF Bosco, J Bruyere, MG Sanda	07/24/2015
Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. The Journal of urology	C de la Calle, D Patil, JT Wei, DS Scherr, L Sokoll, DW Chan, J Siddiqui, JM Mosquera, MA Rubin, MG Sanda	07/01/2015
The prostate health index selectively identifies clinically significant prostate cancer. The Journal of urology	S Loeb, MG Sanda, DL Broyles, SS Shin, CH Bangma, JT Wei, AW Partin, GG Klee, KM Slawin, LS Marks, RH van Schaik, DW Chan, LJ Sokoll, AB Cruz, IA Mizrahi, WJ Catalona	04/01/2015
Benchmarks for operative outcomes of robotic and open radical prostatectomy: results from the Health Professionals Follow-up Study. European urology	M Alemozaffar, M Sanda, D Yecies, LA Mucci, MJ Stampfer, SA Kenfield	03/01/2015
Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology	ME Taplin, B Montgomery, CJ Logothetis, GJ Bubley, JP Richie, BL Dalkin, MG Sanda, JW Davis, M Loda, LD True, P Troncoso, H Ye, RT Lis, BT Marck, AM Matsumoto, SP Balk, EA Mostaghel, TM Penning, PS Nelson, W Xie, Z Jiang, CM Haqq, D Tamae, N Tran, W Peng, T Kheoh, A Molina, PW Kantoff	11/20/2014
Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Human pathology	K Park, Z Chen, TY MacDonald, J Siddiqui, H Ye, A Erbersdobler, MM Shevchuk, BD Robinson, MG Sanda, AM Chinnaiyan, H Beltran, MA Rubin, JM Mosquera	10/01/2014
Localized prostate cancer in Norway, the United States, and Spain: between-country differences of variables before treatment among patients eligible for curative treatment. Clinical genitourinary cancer	AH Storås, MG Sanda, M Ferrer, JH Loge, AA Dahl, EA Steinsvik, F Guedea, M Cvancarova, SD Fosså	08/01/2014
Androgens alter T-cell immunity by inhibiting T-helper 1 differentiation. Proceedings of the National Academy of Sciences of the United States of America	HT Kissick, MG Sanda, LK Dunn, KL Pellegrini, ST On, JK Noel, MS Arredouani	07/08/2014
Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials. Journal of the National Cancer Institute	RC Chen, P Chang, RJ Vetter, H Lukka, WA Stokes, MG Sanda, D Watkins-Bruner, BB Reeve, HM Sandler	07/01/2014
Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer. Urology	DP Ankerst, J Hoefler, S Bock, PJ Goodman, A Vickers, J Hernandez, LJ Sokoll, MG Sanda, JT Wei, RJ Leach, IM Thompson	06/01/2014
Satisfaction with information used to choose prostate cancer treatment. The Journal of urology	SM Gilbert, MG Sanda, RL Dunn, TK Greenfield, L Hembroff, E Klein, CS Saigal, L Pisters, J Michalski, HM Sandler, MS Litwin, JT Wei	05/01/2014
Dose to the inferior rectum is strongly associated with patient reported bowel quality of life after radiation therapy for prostate cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology	MH Stenmark, AS Conlon, S Johnson, S Daignault, D Litzenberg, R Marsh, T Ritter, S Vance, N Kazzi, FY Feng, H Sandler, MG Sanda, DA Hamstra	02/01/2014
Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response. PloS one	HT Kissick, MG Sanda, LK Dunn, MS Arredouani	01/01/2014
Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer. Cancer immunology, immunotherapy : CII	HT Kissick, MG Sanda, LK Dunn, MS Arredouani	12/01/2013
Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology	HA Gay, JM Michalski, DA Hamstra, JT Wei, RL Dunn, EA Klein, HM Sandler, C Saigal, M Litwin, D Kuban, L Hembroff, P Chang, MG Sanda	12/01/2013
Survivorship after prostate cancer treatment: spouses' quality of life at 36 months. Oncology nursing forum	J Harden, MG Sanda, JT Wei, HN Yarandi, L Hembroff, J Hardy, L Northouse	11/01/2013

Awards

J. Hartwell Harrison Memorial Resident Education Award (2012)
Harvard-Longwood Urology Residency
Visiting Professor (2012)
Memorial Sloan Kettering Cancer Center
Honorary Degree: Master of Arts (2011)
Harvard University
Service Recognition Award for 3-year term as Chair, EDRN Prostate/GU Collaborative Group (2010)
National Cancer Institute
Leadership Development for Physicians at Academic Health Centers (Select Course at Harvard School of Public Health) (2010)
Nominated by Senior Leadership at BIDMC
Best of Boston - Top Doctors (Urology) (2005-2012)
Boston Magazine
Society of Urological Oncology Young Investigator Award (2005)
Society of Urological Oncology

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.9	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	05/17/2025	Dr. Sanda is the best urologist
One star One star One star One star One star	05/12/2025	This was a consultation for cancer treatment options. All of the professionals I spoke to provided excellent information and answered questions well. I was extremely pleased with the preparation and thought of all of the professionals. Dr. Sanda especially provided very good Information for decision making. I couldn't have been more pleased.
One star One star One star One star One star	05/08/2025	Very good
One star One star One star One star One star	04/20/2025	Already recommended to others
One star One star One star One star One star	04/17/2025	Dr Sanda is great at explaining options and next steps.
One star One star One star One star One star	04/12/2025	Dr. Sanda spent a lot of time explaining everything about my cancer diagnosis and what it meant for me, specifically given my medical history, age, and test results. This was a second opinion, and I am SO GLAD I came to Emory. I have never had a doctor take such care and time, helping me understand my diagnosis and my options. Dr. Dhere was also very helpful and informative, but Dr. Sanda was exceptional.
One star One star One star One star One star	04/12/2025	It was a very good Experience for me.
One star One star One star One star One star	04/10/2025	He expressed concern about my problem
One star One star One star One star One star	04/06/2025	Dr. Sanda had reviewed my health history prior to the telemed meeting. He was very perpared for this meeting.
One star One star One star One star One star	04/03/2025	Exceptionally good dialog between Dr, patient & family
One star One star One star One star One star	04/03/2025	Dr. Sanda is fantastic!!
One star One star One star One star One star	03/27/2025	Both doctors, patient advocate and staff were excellent
One star One star One star One star One star	03/27/2025	Emory is the gold standard, not just in the quality of care but also how patients (me) are treated. Emory stands out.
One star One star One star One star One star	03/20/2025	Great professional service with caring and understanding manner.
One star One star One star One star One star	03/13/2025	Good
One star One star One star One star One star	02/25/2025	Dr Sanda was exceptional in discussing options and showed concern
One star One star One star One star One star	02/13/2025	Dr. Sanda explained the results and discussed with me in a caring, professional and easy to understand manner the plan to follow.
One star One star One star One star One star	02/06/2025	Dr. Sanda was very patient with our questions and all explanations were written down for us to review. He was very comprehensive with explanations about my condition and my options for treatments and monitoring.
One star One star One star One star One star	01/11/2025	Doctor even helped us figure out our audio problem on live link
One star One star One star One star One star	12/20/2024	Good
One star One star One star One star One star	12/19/2024	Excellent and efficient
One star One star One star One star One star	12/14/2024	Dr Sanda is outstanding, in my opinion
One star One star One star One star One star	11/09/2024	Dr. Sanda is wonderful. Always concerned and empathetic.
One star One star One star One star One star	10/31/2024	Very Good
One star One star One star One star One star	10/24/2024	Good
One star One star One star One star One star	10/17/2024	Enjoyed chatting with Dr Sanda about sailing.
One star One star One star One star One star	09/21/2024	Excellent experience with Dr Sanda. Very professional and knowledgeable. He is an excellent physician
One star One star One star One star One star	09/14/2024	Dr Sanda explained my findings in a clear and concise manner. He effectively utilized a diagram to demonstrate what the pathology looks like, which is something I wondered. He also effectively explained my odds in a numerical fashion.
One star One star One star One star One star	09/14/2024	Dr. Sanda is outstanding!
One star One star One star One star One star	08/31/2024	Dr. Sanda is a superstar, period. An outstanding physician, and aa wonderful, compassionate human being.
One star One star One star One star One star	08/30/2024	Dr. Sands is a consummate professional!
One star One star One star One star One star	08/25/2024	Provider's recommendation always in the patient favor. Closest location, best timing, etc
One star One star One star One star One star	08/01/2024	Dr Sanda and staff were very thorough in describing and recommending my plan of action. I am anxiously waiting to begin.
One star One star One star One star One star	07/25/2024	I appreciate Dr. Sanda and his team.
One star One star One star One star One star	07/25/2024	Great communications. Very concerned! ! Great competency!
One star One star One star One star One star	07/23/2024	I was very happy for the way Dr Sanda was able to explain my concerns, he really gave me confidence that everything will be alright
One star One star One star One star One star	07/06/2024	Dr. Sandra was patient, a good listener and clear in his evaluation.
One star One star One star One star One star	06/28/2024	Excellent provider
One star One star One star One star One star	06/27/2024	Dr. Sanda is the best ever!